Agrippal S1 (influenza vaccine): Uses, Dosage & Side Effects

What it's for (Indications)

The influenza vaccine, exemplified by brands such as Influvac, is primarily indicated for active immunization against influenza virus disease caused by the influenza virus types A and B strains contained in the vaccine.
Annual vaccination is a critical public health measure recommended for individuals aged 6 months and older to reduce the risk of influenza infection, its associated morbidity, and mortality.
The specific viral strains included in the vaccine are determined annually by global health authorities, such as the World Health Organization (WHO), based on surveillance data predicting the most prevalent strains for the upcoming influenza season (e.
g.
, A/H1N1, A/H3N2, and one or two B lineage viruses).
This prophylactic measure is particularly crucial for individuals at high risk of developing severe influenza-related complications, including the elderly (≥65 years), young children, pregnant women, individuals with chronic medical conditions (e.
g.
, asthma, diabetes, heart disease, chronic kidney disease, neurological disorders), residents of nursing homes and other long-term care facilities, and healthcare personnel.
The vaccine aims to prevent influenza illness, decrease the severity of symptoms, reduce hospitalization rates, and lower the incidence of secondary complications such as bacterial pneumonia, exacerbations of underlying chronic diseases, and influenza-associated deaths.

Dosage Information

Type	Guideline
Standard	The dosage of influenza vaccine is dependent on the recipient's age and specific vaccine formulation (e.g., standard dose, high-dose, or specific pediatric preparations). For most adults and children aged 3 years and older, the recommended dosage is a single intramuscular (IM) injection of 0.5 mL administered annually, typically into the deltoid muscle. For pediatric patients aged 6 months to less than 3 years, the standard dosage is usually 0.25 mL administered intramuscularly into the anterolateral aspect of the thigh or the deltoid muscle, based on muscle mass adequacy. Children aged 6 months to 8 years who have not previously received influenza vaccination, or whose vaccination history is unknown, typically require two doses of vaccine administered at least 4 weeks apart to achieve optimal immune protection; subsequent annual vaccinations for this age group then consist of a single dose. High-dose influenza vaccines, containing a greater antigen quantity (e.g., 60 mcg of hemagglutinin per strain), are specifically indicated for individuals 65 years of age and older to elicit a more robust immune response. Vaccination should ideally occur before the onset of influenza activity in the community, typically during the autumn months, to allow sufficient time for protective antibody levels to develop, which usually takes about two weeks post-vaccination. Intradermal and intranasal formulations also exist but follow specific dosing and administration guidelines.

Type

Guideline

Standard

The dosage of influenza vaccine is dependent on the recipient's age and specific vaccine formulation (e.g., standard dose, high-dose, or specific pediatric preparations). For most adults and children aged 3 years and older, the recommended dosage is a single intramuscular (IM) injection of 0.5 mL administered annually, typically into the deltoid muscle. For pediatric patients aged 6 months to less than 3 years, the standard dosage is usually 0.25 mL administered intramuscularly into the anterolateral aspect of the thigh or the deltoid muscle, based on muscle mass adequacy. Children aged 6 months to 8 years who have not previously received influenza vaccination, or whose vaccination history is unknown, typically require two doses of vaccine administered at least 4 weeks apart to achieve optimal immune protection; subsequent annual vaccinations for this age group then consist of a single dose. High-dose influenza vaccines, containing a greater antigen quantity (e.g., 60 mcg of hemagglutinin per strain), are specifically indicated for individuals 65 years of age and older to elicit a more robust immune response. Vaccination should ideally occur before the onset of influenza activity in the community, typically during the autumn months, to allow sufficient time for protective antibody levels to develop, which usually takes about two weeks post-vaccination. Intradermal and intranasal formulations also exist but follow specific dosing and administration guidelines.

Safety & Warnings

Common Side Effects

The vast majority of adverse reactions to influenza vaccines are mild to moderate in severity and typically resolve spontaneously within one to two days.
Common local reactions at the injection site include pain, tenderness, redness (erythema), swelling, and induration.
These local reactions are generally transient and are indicative of the immune system's response.
Systemic adverse reactions, though less common than local reactions, can include headache, muscle aches (myalgia), malaise, fatigue, low-grade fever, and nausea.
It is crucial to distinguish these mild, transient symptoms from actual influenza illness, as inactivated vaccines do not contain live virus and cannot cause influenza.
More serious, albeit rare, adverse events can occur.
These include allergic reactions, ranging from mild urticaria and rash to severe anaphylaxis, which is a life-threatening systemic allergic response requiring immediate medical intervention.
Neurological complications, such as Guillain-Barré Syndrome (GBS), have been reported in very rare instances following influenza vaccination, with epidemiological studies estimating an excess risk of approximately 1-2 cases per million vaccine doses, though the risk of GBS from influenza infection itself is substantially higher.
Syncope (fainting) is another potential adverse event, particularly in adolescents and young adults, often occurring immediately after vaccination, which necessitates observation to prevent injury from falling.

Serious Warnings

Black Box Warning: The influenza vaccine (e.g., Influvac) does not carry an FDA-mandated Black Box Warning. However, it is imperative for healthcare providers and vaccine recipients to be fully aware of certain serious warnings and potential adverse events, which are critical for ensuring patient safety and appropriate clinical management. **Serious Warnings:** 1. **Anaphylaxis and Severe Allergic Reactions:** While rare, severe allergic reactions, including life-threatening anaphylaxis, can occur following the administration of influenza vaccines. Symptoms may include urticaria, angioedema, respiratory distress (e.g., bronchospasm, laryngeal edema), hypotension, and circulatory collapse. Healthcare providers must be prepared to manage anaphylaxis immediately, with appropriate medical therapies such as epinephrine readily available. All vaccine recipients should be observed for a minimum of 15 minutes post-vaccination to monitor for acute reactions. Individuals with a documented history of severe allergic reactions to any vaccine component or to a previous dose of influenza vaccine should not receive the vaccine. 2. **Guillain-Barré Syndrome (GBS):** Reports of Guillain-Barré Syndrome, a serious neurological disorder characterized by progressive muscle weakness and paralysis, have been temporally associated with influenza vaccination. Although the overall risk is extremely low (estimated at approximately 1-2 excess cases per million vaccine doses), and the risk of GBS from influenza infection itself is substantially higher, individuals with a history of GBS within 6 weeks following a prior influenza vaccination should be carefully evaluated by their healthcare provider. The decision to vaccinate in such cases should weigh the potential benefits of influenza prevention against the theoretical risk of GBS recurrence. 3. **Syncope (Fainting):** Syncope can occur after, or even before, any injectable vaccination, particularly in adolescents and young adults. This can lead to injury from falling. Healthcare providers should ensure that patients are seated or lying down during vaccination and observed for 15 minutes afterward to prevent fall-related injuries. 4. **Limitations of Protection:** The influenza vaccine provides protection only against the specific influenza strains included in the vaccine formulation and does not provide immunity against all respiratory illnesses or against influenza strains not covered by the vaccine. Annual vaccination is required due to the continuous antigenic drift of influenza viruses, necessitating updated vaccine formulations.
While influenza vaccines are generally considered safe and efficacious, several important warnings and precautions are essential for patient safety and optimal vaccine effectiveness.
Individuals with a history of Guillain-Barré Syndrome (GBS) that occurred within 6 weeks following a previous influenza vaccination should have their risk/benefit profile carefully assessed by a healthcare provider, as the decision to vaccinate requires individualized clinical judgment considering the potential benefits of flu prevention versus the theoretical risk of GBS recurrence.
Vaccination should be postponed for individuals experiencing a moderate or severe acute illness with or without fever until their condition has improved, to avoid confounding the diagnosis of potential vaccine-related adverse events.
Patients with bleeding disorders or those on anticoagulant therapy should be vaccinated with caution; appropriate techniques, such as applying firm pressure to the injection site for several minutes, should be employed to minimize the risk of hematoma formation.
While modern influenza vaccines contain minimal egg protein, individuals with severe, life-threatening egg allergies should receive egg-based vaccines under the supervision of a healthcare provider equipped to manage severe allergic reactions, or consider recombinant or cell culture-based egg-free alternatives if available.
It is important to emphasize that the influenza vaccine provides specific protection only against the influenza virus strains included in the vaccine formulation and does not protect against other respiratory viruses or influenza strains not covered by the vaccine.
Healthcare providers should also be aware of the risk of syncope following vaccination, particularly in adolescents and young adults, and take appropriate precautions to prevent fall-related injuries.

How it Works (Mechanism of Action)

The mechanism of action for inactivated influenza vaccines, including Influvac, involves the introduction of viral antigens into the host's immune system to stimulate an active immune response without causing disease. These vaccines contain inactivated (killed) whole or split influenza virus particles, or purified surface antigens (hemagglutinin and neuraminidase proteins), from the specific strains predicted to circulate in the upcoming season. Upon intramuscular administration, antigen-presenting cells (APCs), such as macrophages and dendritic cells, process these viral antigens and present them on their surface to T helper cells. This interaction, along with direct stimulation of B lymphocytes, leads to the activation and proliferation of antigen-specific B cells, which differentiate into plasma cells that produce antibodies. The most critical antibodies generated are those targeting the hemagglutinin (HA) protein, which plays a vital role in viral attachment and entry into host cells. These anti-HA antibodies neutralize the virus by preventing its binding to respiratory epithelial cells, thereby blocking infection. The vaccine also elicits a cellular immune response, involving cytotoxic T lymphocytes (CTLs), which can recognize and eliminate influenza-infected cells. This acquired humoral and cellular immunity provides protection against subsequent exposure to homologous or antigenically similar influenza virus strains. Due to the influenza virus's propensity for antigenic drift (minor mutations), annual vaccination is necessary to maintain effective protection against evolving circulating strains.